PRESS RELEASE
Infosys Public Services to Set up Testing Center of Excellence and Consolidate
IT Services for Prime Therapeutics LLC
ROCKVILLE, Md. - March 27, 2014: Infosys Public Services, Inc., a U.S. based
subsidiary of Infosys, today announced that it has been selected by Prime
Therapeutics LLC (Prime Therapeutics), a leading pharmacy benefit manager
(PBM), to set up a testing center of excellence (COE) and consolidate the
delivery of its application testing services as part of a new three-year
contract.
Prime Therapeutics will streamline and optimize its quality assurance (QA) and
testing services as well as enhance its competitiveness with Infosys Public
Services' expertise and world-class delivery model. Prime Therapeutics also
expects to expand the capabilities of its QA organization and gain efficiencies
in managing a large scale QA department.
"We look forward to bringing our deep experience in the health care industry
and pharmacy benefit management in particular as well as globally benchmarked
QA and testing service delivery to Prime Therapeutics," said Eric Paternoster,
President & CEO, Infosys Public Services, Inc. "This agreement will allow us to
help the company sharpen its focus on providing better care and services to
their members."
Highlights:
* Prime Therapeutics selected Infosys Public Services for its health care and
pharmacy benefit management expertise, proven experience with QA and
testing COEs, and service delivery capabilities.
* As part of the contract, Infosys Public Services will consolidate and
standardize Prime Therapeutics' QA and testing services, currently provided
by multiple service providers.
* Infosys Public Services will support Prime Therapeutics' QA organization as
they deliver across all lines of the business and increase the agility of
the QA department.
* Prime Therapeutics will be able to improve application and service quality,
and reduce IT costs with Infosys Public Services' range of QA and testing
frameworks, techniques, tools and accelerators.
"The rapidly evolving health care industry demands faster response and improved
information technology quality to ensure Prime Therapeutics' competitiveness,"
said Jim Graham, Vice President Application Development, Prime Therapeutics.
"Transforming our testing and QA services will help us achieve that and better
meet the needs of health plans, employers, and government programs."
About Infosys Public Services, Inc.
Infosys Public Services, a U.S. based subsidiary of Infosys (NYSE:INFY), is a
leader in business consulting and technology solutions. We partner with
healthcare and public sector organizations to help them stay ahead of the
innovation curve. Our solutions, combined with execution excellence and proven
best practices, allow clients to optimize their operations today while building
tomorrow's enterprise. Visit www.infosyspublicservices.com to learn more.
About Infosys
Infosys is a global leader in consulting, technology and outsourcing solutions.
We enable clients, in more than 30 countries, to stay a step ahead of emerging
business trends and outperform the competition. We help them transform and
thrive in a changing world by co-creating breakthrough solutions that combine
strategic insights and execution excellence. Visit www.infosys.com to see how
Infosys (NYSE: INFY), with $7.4B in annual revenues and 158,000+ employees, is
Building Tomorrow's Enterprise® today.
Safe Harbor
Certain statements in this release concerning our future growth prospects are
forward-looking statements, which involve a number of risks and uncertainties
that could cause actual results to differ materially from those in such
forward-looking statements. The risks and uncertainties relating to these
statements include, but are not limited to, risks and uncertainties regarding
fluctuations in earnings, fluctuations in foreign exchange rates, our ability
to manage growth, intense competition in IT services including those factors
which may affect our cost advantage, wage increases in India, our ability to
attract and retain highly skilled professionals, time and cost overruns on
fixed-price, fixed-time frame contracts, client concentration, restrictions on
immigration, industry segment concentration, our ability to manage our
international operations, reduced demand for technology in our key focus areas,
disruptions in telecommunication networks or system failures, our ability to
successfully complete and integrate potential acquisitions, liability for
damages on our service contracts, the success of the companies in which Infosys
has made strategic investments, withdrawal or expiration of governmental fiscal
incentives, political instability and regional conflicts, legal restrictions on
raising capital or acquiring companies outside India, and unauthorized use of
our intellectual property and general economic conditions affecting our
industry. Additional risks that could affect our future operating results are
more fully described in our United States Securities and Exchange Commission
filings including our Annual Report on Form 20-F for the fiscal year ended
March 31, 2013 and on Form 6-K for the quarter ended December 31, 2013.These
filings are available at www.sec.gov. Infosys may, from time to time, make
additional written and oral forward-looking statements, including statements
contained in the company's filings with the Securities and Exchange Commission
and our reports to shareholders. The company does not undertake to update any
forward-looking statements that may be made from time to time by or on behalf
of the company unless it is required by law.
For further information, please contact:
EMEA Asia Pacific The Americas
Paul de Lara Sadaf Khan Tara Kozak-Lindsay
Infosys, UK Infosys, India GolinHarris
+44 2075162748 +91 80 4156 4971 +1-212-373-6020
Paul_deLara@infosys.com Sadaf_Khan03@infosys.com TKozakLindsay@golinharris.com